No Data
No Data
Janux Therapeutics Initiated With an Outperform at Leerink
Evaluating Janux Therapeutics: Insights From 6 Financial Analysts
Janux Therapeutics Initiated at Outperform by Leerink Partners
Leerink Partners Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $79
Padres Pedal the Cause Is Now Curebound Cancer Challenge, Kicks Off With $1.1 Million Philanthropic Gift as Organization Doubles Down on Mission to End Cancer
10 Health Care Stocks Whale Activity In Today's Session
No Data
No Data